the diagnosis of MDS may improve prognosis due to a lower treatment-related mortality and a lower relapse risk.
Young patients with and sAML had a 5-year DFS of 52, 34, 19 and 26%, advanced MDS may achieve prolonged, disease-free surrespectively. The 5-year OS for the respective patient vival when treated with intensive antileukemic chemogroups was 57, 42, 24 and 28%. In a multivariate analytherapy. 6 However, remission duration has generally been sis, younger age, shorter disease duration, and absence short. 7 Nowadays, allogeneic BMT is considered the treatof excess of blasts were associated with improved outment of choice for younger patients with histocompatible come. From these data we conclude that patients with siblings. The timing of transplant in the management of myelodysplasia who have appropriate marrow donors, the disease remains controversial. European BMT centers especially those aged less than 40 years and those with generally administer remission induction treatment prior to low medullary blast cell count should be treated with BMT, particularly in advanced cases of MDS. 8, 9 In contrast, BMT as the primary treatment early in the course of most patients with MDS in North America have been transtheir disease. Transplantation early after establishing planted without prior induction chemotherapy. 10 The previous largest series reported 62 patients with HLA-identical sibling donors 11 of whom only 75% had MDS according
Correspondence: V Runde, Department of Bone Marrow Transplantation, to FAB criteria. The probability of disease-free survival of of BMT as first-line therapy has not been resolved to date plasia had progressed to AML at the time of BMT. Cytogenetic analyses were reported for 34 patients; 11 of them these data require independent confirmation. We have retrospectively analyzed the outcome of HLA-identical sibling had a normal karyotype, 18 patients presented with single and five with complex clonal aberrations. BMT in 131 patients with MDS or sAML who did not receive conventional induction treatment prior to BMT.
Treatment
Only patients treated with bone marrow from an HLAPatients and methods identical sibling were included in this analysis. The transplant was performed after consent of the patient and donor Study population and after approval of the Ethical Practice Committees Questionnaires were sent to all centers that had reported according to the local and national policies. Conditioning cases of MDS, sAML and post-cytotoxic MDS/AML to the regimens varied from center to center. Most patients (70%) Chronic Leukemia Working Party and the Acute Leukemia received total body irradiation (TBI) as part of the conWorking Party of the European Cooperative Group for ditioning regimen. The other patients received conditioning Blood and Marrow Transplantation (EBMT). Centers were with chemotherapy alone. Immunosuppression consisted of asked to provide additional clinical information for patients cyclosporin A and MTX, or cyclosporin A alone in the transplanted for these diseases and to send peripheral blood majority of cases. Only a few patients were treated with and bone marrow smears performed prior to BMT. Data MTX alone, and 12% received T cell-depleted bone marfrom 131 patients treated from 1983 to 1994 (Table 1) in row for graft-versus-host disease prevention. 44 centers, and peripheral blood and bone marrow slides from 30 patients were collected. In 15 patients MDS or AML was considered to be of post-cytotoxic origin as a Statistical analysis history of radio-and/or chemotherapy for Hodgkin's disease or other primary diseases was reported. The other The Kaplan-Meier product limit method was employed to cases were considered to be primary MDS. The median age estimate survival, disease-free survival (DFS), relapse inciat the time of BMT was 33 years (range, 2-55 years) and dence and transplant-related mortality. All were measured included 11 patients younger than 16 years. Median disease from the day of BMT to death or last follow-up. Log-rank duration was 7 months (range, 1-218 months). Treatment analysis was used to compare survival curves. Multivariate prior to BMT was restricted to supportive measures such modeling was performed using the stepwise proportional as transfusions and antibiotic therapy except for four hazard regression model. patients who received one or more courses of low-dose cytosine arabinoside without achieving remission. Fourteen patients with a documented history of primary myelodys-
Results

Table 1
Clinical and transplantation characteristics of 131 patients
In 21 of 30 cases, central bone marrow cytology review undergoing BMT as first-line treatment confirmed the FAB diagnosis reported by the local center.
Characteristic Data
Analysis of treatment outcome only referred to the FAB diagnosis made by the BMT center at the time of transplant.
Patients studied (n) 131
Cumulative overall survival, DFS, relapse risk and transAge median (range) years 33 plant-related mortality (TRM) 5 years after BMT are given
in Table 2 . demonstrated a shorter overall survival for patients aged BMT in patients with myelodysplastic syndromes V Runde et al 257 Table 2 Cumulative probability at 5 years for overall survival, disease-free survival, relapse risk and transplant-related mortality *at 18 months; **over 18 months. SE = standard error (%); DFS = disease-free survival; TRM = transplant-related mortality; RA = refractory anemia; RARS = refractory anemia with ring sideroblasts; RAEB = refractory anemia with excess of blasts; RAEB/T = refractory anemia with excess of blasts in transformation; CMML = chronic myelomonocytic leukemia; sAML = secondary acute myeloid leukemia.
above 40 years (P = 0.05) and for patients with a disease duration between 4 and 12 months (P = 0.03) (Figure 1 ). Differences in survival between primary (43%) and postcytotoxic MDS (32%) and between patients with (27%) and without (42%) T cell depletion did not reach statistical significance. Multivariate analysis using the covariates age, disease duration, diagnosis at BMT, T cell depletion and etiology of the disease showed that diagnosis of RAEB, RAEB/T and sAML and a disease duration of more than 3 months were predictors for shorter survival (Table 3) .
Transplant-related mortality (TRM) and relapse
Fifty patients died from transplant-related complications after a median interval of 2 months (range, 0-99 months).
The main causes of TRM were acute GVHD in 13 patients, bacterial infection in eight patients, haemorrhage in six patients, and GVHD associated with interstitial pneumonitis (IP) in four patients. Cumulative probability of TRM for the entire group of patients at 5 years was 44%. Univariate analysis showed a lower incidence of TRM in younger patients (P = 0.01) (Figure 2 ), in patients with a disease duration below 4 months (P = 0.05), and in patients with showed a significantly lower risk of relapse in patients with BMT in patients with myelodysplastic syndromes V Runde et al 258 The underlined 95% confidence interval (CI) denotes significant differences.
48% at 18 months in patients receiving T cell-depleted marrow.
Disease-free survival (DFS)
At the time of analysis 53 patients were alive and diseasefree. The cumulative 5-year DFS for the entire group of patients was 34%. Patients with RA/RARS, RAEB, RAEB/T and sAML had an actuarial 5-year DFS of 52, 34, 19 and 26%, respectively (P = 0.01) (Figure 3) . One of the four patients with CMML was alive without evidence of disease 62 months after BMT. Two CMML patients relapsed and died after 2 and 24 months, respectively, and one CMML patient died from pulmonary hemorrhage 2 weeks after BMT. Multivariate analysis showed that dis- a disease duration of more than 12 months (P = 0.01). Multivariate analysis demonstrated that RAEB/T (P = 0.02) and disease duration over 3 months (P = 0.04) were associated with a higher TRM.
Relapses occurred in 28 patients after a median interval of 4 months (range, 1-33 months). Seven relapses were diagnosed beyond 12 months. Five-year actuarial probability of relapse in patients with RA/RARS, RAEB, RAEB/T and sAML was 13, 44, 52 and 50%, respectively (P = 0.04). Univariate analysis showed a significantly lower risk of relapse in patients with a disease duration of more than 12 months (P = 0.01). Multivariate analysis demonstrated that RAEB, RAEB/T, and sAML patients had a significantly higher relapse risk when compared to RA/RARS patients. In addition, T cell depletion was identified as a variable associated with a higher relapse risk, which was ease duration of more than 3 months, RAEB, RAEB/T, and with bone marrow blasts between 5 and 20% (RAEB) had an intermediate outcome with DFS rates and relapse rates sAML were associated with a shorter DFS.
close to those of the entire group. Finally, patients with RAEB/T or sAML had 5-year DFS rates of only 19 and 26%, respectively. Previous reports have shown that patients with RAEB/T Discussion have an excellent response to conventional antileukemic therapy, with remission rates approaching 65%. 6 From In this retrospective study we analyzed data from 44 European centers that performed BMT for patients with MDS these data and the high relapse rate of RAEB/T and sAML patients reported in our paper, one might propose that alloor sAML between 1983 and 1994. For this analysis we selected all patients registered in the MDS Registry of the geneic BMT may be performed as second-line treatment in the majority of patients with increased medullary blast cell European Cooperative Group for Blood and Marrow Transplantation in Leiden who underwent BMT with an HLAcounts. The successful use of induction chemotherapy may just select out patients who are less likely to relapse with identical sibling. The aim of our study was to evaluate the therapeutic value of allogeneic BMT in a disease which is transplantation because of the inherent characteristics of their disease. Subcategories of RAEB/T or sAML patients rare in patients younger than 50 years. In order to select a homogeneously pretreated and transplanted patient group, may be identified who have a low probability of entering CR after remission-induction therapy, such as patients with we analyzed data from patients who underwent BMT as primary cytoreductive treatment. The cumulative 5-year certain cytogenetic characteristics or patients with a longer history of MDS. In these patients alternative treatment, DFS rate was 34%. This result is similar to that reported in four smaller, heterogeneous series of patients (Table 4) . [11] [12] [13] [14] aimed at reducing the risk of relapse after transplantation with a more intensive preparative regimen or postOnly one study from Detroit 15 which included relatively few patients and with a short follow-up (median, 20 transplant immunomodulation, could be applied. Future studies should attempt to identify these patients. months) reported better results with a DFS of 62%. All five reports included patients who have been pretreated with With regard to the results of our central review of bone marrow slides, it should be emphasized, that in most cases chemotherapy which makes interpretation of the data rather difficult. Our analysis, therefore, supports the conclusion (21/30) there was complete agreement. In nine cases a modification of the MDS FAB sub-classification was necesthat BMT performed as primary treatment in MDS may cure approximately one-third of patients.
sary. No major differences were observed. With respect to the importance of the bone marrow blast percentage for the Disease-free survival and relapse rates were mainly dependent on pre-transplant FAB diagnosis. Patients withoutcome of MDS patients after BMT, prospective studies with a central morphology review are required. An ongoing out excess blasts had an excellent prognosis with a 5-year DFS of 52% and a relapse risk of only 13%. In the multiprospective joint study of the EORTC and EBMT which includes a central BM review combines remission induction variate analysis this patient group showed a statistically significant better DFS, overall survival, and a lower risk of chemotherapy and BMT in MDS patients with more than 10% bone marrow blasts or complex chromosomal relapse in comparison to the other FAB subtypes. Patients aberrations. 
DFS = disease-free survival; TRM = transplant-related mortality; Bu = busulfan; Cy = cyclophosphamide; VP = etoposide; Ar = cytosine arabinoside; TBI = total body irradiation; TLI = total lymphoid irradiation.
